ERBB2 and breast cancer: For HR‐positive breast cancer, KI67 ≥ 20 was more prevalent in the HER2‐low group, whereas it was less common in TNBC (58.1% vs. 52.3%, p < 0.001 and 84.8% vs. 93.5%, p < 0.001, respectively).